Demineralized Bone Matrix Market Size (2024 - 2029)

Demineralized Bone Matrix Market Analysis

The demineralized bone matrix market is expected to register a CAGR of 5.5% over the forecast period.

Delays in orthopedic care and services during the COVID-19 pandemic adversely impacted the market. According to the NCBI research study published in August 2021, orthopedic residency training was postponed or canceled during the pandemic. The inevitable halting of all elective surgeries has limited hands-on practice and exposure to several procedures. Although the orthopedic oncology service has continued, it is a limited area within the orthopedic training program, including at least nine sub-specialties. Trauma surgery continued but at a much slower rate, most likely due to the nationwide lockdown, which had a short-term negative impact on the market. In March 2020, the International Olympic Committee postponed the 2020 Tokyo Olympics and Paralympics to 2021. According to the CovidSurg Collaborative, a research initiative by 120 countries, 28.4 million elective surgeries were reported to have been canceled in 2020, including 6.3 million orthopedic surgeries. However, with a decrease in the number of cases of COVID-19 and the resumption of various healthcare services, the market gained traction and is anticipated to continue its upward trend over the forecast period.

Factors such as the increasing incidence of orthopedic disorders, the rising number of spinal fusion and dental surgeries, and the increasing patient base with a growing population are expected to drive the market's growth. For instance, according to the WHO Key Facts on Musculoskeletal Health published in July 2022, around 1.71 billion people worldwide had musculoskeletal conditions. In Europe, the International Osteoporosis Foundation (IOF) is responsible for raising awareness of osteoporosis care in Europe. According to an article published by the National Institute of Health, in 2021, the incidence of osteoarthritis in the United Kingdom was 6.8 per 1,000 people, whereas the prevalence was around 10.7% in 2021. Thus, such a high prevalence of orthopedic disorders is expected to propel the demand for demineralized bone matrix, as it one of the important therapeutic options for such conditions.

As per the Australian Institute of Health and Welfare's article on chronic musculoskeletal conditions published in July 2022, around 6.9 million people in Australia were affected by musculoskeletal disorders during 2020-2021. Over 3.1 million people had arthritis, and more than 889 thousand people had osteoporosis. According to the US CDC article on arthritis, updated in October 2021, around 58.5 million people in the nation had doctor-diagnosed arthritis. The article estimated that, by 2040, over 78.4 million adults in the United States will be affected by arthritis. Thus, owing to such factors, considerable market growth is expected over the forecast period.

However, the high cost of demineralized bone matrix is expected to hinder the market's growth over the forecast period.

Demineralized Bone Matrix Industry Segmentation

As per the scope of the report, a demineralized bone matrix (DBM) is an osteoconductive scaffold that is manufactured by acid extraction of allograft bone resulting in the retention of collagen and non-collagenous proteins, including growth factors. These components make DBM both osteoinductive and osteoconductive. 

The demineralized bone matrix market is segmented by product type (gel, putty, and other product types), application (dental, craniomaxillofacial, joint reconstruction, spinal fusion, and other applications), geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above segments.